TerminatedNCT04049071
TARGET GCAT Registry
Studying Giant cell arteritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Leeds
- Principal Investigator
- Ann MorganUniversity of Leeds
- Enrollment
- 80 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2019 – 2020
Study locations (30)
- Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, United Kingdom
- Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Royal Derby Hospital, University Hospital of Derby and Burton NHS Foundation Trust, Derby, United Kingdom
- Ninewells Hospital and Medical School, NHS Tayside, Dundee, United Kingdom
- NHS Lothian, Edinburgh, Edinburgh, United Kingdom
- Inverclyde Royal Hospital, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- Royal Alexandra Hospital, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- Vale of Leven Hospital, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
- Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom
- Airedale General Hospital, Airedale NHS Foundation Trust, Keighley, United Kingdom
- Royal Lancaster & Westmorland General, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, United Kingdom
- Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom
- Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- Aintree University Hospital, Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom
- Royal Glamorgan Hospital, Cwm Taf University Health Board, Llantrisant, United Kingdom
- +15 more locations on ClinicalTrials.gov
Collaborators
University of Oxford · Hoffmann-La Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04049071 on ClinicalTrials.govOther trials for Giant cell arteritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07108387Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell ArteritisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT07084480Giant Cell Arteritis - Ways to Precision MedicineWuerzburg University Hospital
- RECRUITINGNANCT07001059oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSoundHôpital NOVO
- RECRUITINGNCT06894602Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell ArteritisUniversity Hospital, Brest
- RECRUITINGNCT05749094Optic Nerve Sheath Ultrasound in Giant Cell ArteritisCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- ACTIVE NOT RECRUITINGNCT05703763The Applanation Tonometry in GCA PilotCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- RECRUITINGPHASE2NCT06887062Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)University of Edinburgh
- RECRUITINGNCT06742671Performance of a Fast-track Pathway for Giant Cell Arteritis DiagnosisGroupe Hospitalier de la Rochelle Ré Aunis